Time trends of short-term mortality for octogenarians undergoing a colorectal resection in North Europe.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 08 01 2019
revised: 10 03 2019
accepted: 28 03 2019
pubmed: 21 4 2019
medline: 12 6 2020
entrez: 21 4 2019
Statut: ppublish

Résumé

Decreased cancer specific survival in older colorectal patients is mainly due to mortality in the first year, emphasizing the importance of the first postoperative year. This study aims to gain an overview and time trends of short-term mortality in octogenarians (≥80 years) with colorectal cancer across four North European countries. Patients of 80 years or older, operated for colorectal cancer (stage I-III) between 2005 and 2014, were included. Population-based cohorts from Belgium, Denmark, the Netherlands, and Sweden were collected. Separately for colon- and rectal cancer, 30-day, 90-day, one-year, and excess one-year mortality were calculated. Also, short-term mortality over three time periods (2005-2008, 2009-2011, 2012-2014) was analyzed. In total, 35,158 colon cancer patients and 10,144 rectal cancer patients were included. For colon cancer, 90-day mortality rate was highest in Denmark (15%) and lowest in Sweden (8%). For rectal cancer, 90-day mortality rate was highest in Belgium (11%) and lowest in Sweden (7%). One-year excess mortality rate of colon cancer patients decreased from 2005 to 2008 to 2012-2014 for all countries (Belgium: 17%-11%, Denmark: 21%-15%, the Netherlands: 18%-10%, and Sweden: 10%-8%). For rectal cancer, from 2005 to 2008 to 2012-2014 one-year excess mortality rate decreased in the Netherlands from 16% to 7% and Sweden: 8%-2%). Short-term mortality rates were high in octogenarians operated for colorectal cancer. Short-term mortality rates differ across four North European countries, but decreased over time for both colon and rectal cancer patients in all countries.

Sections du résumé

BACKGROUND BACKGROUND
Decreased cancer specific survival in older colorectal patients is mainly due to mortality in the first year, emphasizing the importance of the first postoperative year. This study aims to gain an overview and time trends of short-term mortality in octogenarians (≥80 years) with colorectal cancer across four North European countries.
METHODS METHODS
Patients of 80 years or older, operated for colorectal cancer (stage I-III) between 2005 and 2014, were included. Population-based cohorts from Belgium, Denmark, the Netherlands, and Sweden were collected. Separately for colon- and rectal cancer, 30-day, 90-day, one-year, and excess one-year mortality were calculated. Also, short-term mortality over three time periods (2005-2008, 2009-2011, 2012-2014) was analyzed.
RESULTS RESULTS
In total, 35,158 colon cancer patients and 10,144 rectal cancer patients were included. For colon cancer, 90-day mortality rate was highest in Denmark (15%) and lowest in Sweden (8%). For rectal cancer, 90-day mortality rate was highest in Belgium (11%) and lowest in Sweden (7%). One-year excess mortality rate of colon cancer patients decreased from 2005 to 2008 to 2012-2014 for all countries (Belgium: 17%-11%, Denmark: 21%-15%, the Netherlands: 18%-10%, and Sweden: 10%-8%). For rectal cancer, from 2005 to 2008 to 2012-2014 one-year excess mortality rate decreased in the Netherlands from 16% to 7% and Sweden: 8%-2%).
CONCLUSIONS CONCLUSIONS
Short-term mortality rates were high in octogenarians operated for colorectal cancer. Short-term mortality rates differ across four North European countries, but decreased over time for both colon and rectal cancer patients in all countries.

Identifiants

pubmed: 31003722
pii: S0748-7983(19)30386-5
doi: 10.1016/j.ejso.2019.03.041
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1396-1402

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Y H M Claassen (YHM)

Department of Surgical Oncology, Leiden University Medical Center, the Netherlands. Electronic address: y.h.m.claassen@lumc.nl.

E Bastiaannet (E)

Department of Surgical Oncology, Leiden University Medical Center, the Netherlands; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.

E van Eycken (E)

National Cancer Registry, Brussels, Belgium.

N Van Damme (N)

National Cancer Registry, Brussels, Belgium.

A Martling (A)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

R Johansson (R)

Department of Radiation Science, Oncology, Umeå University, Umeå, Sweden.

L H Iversen (LH)

Department of Surgery, Aarhus University Hospital, Aarhus, Denmark; Danish Colorectal Cancer Group (DCCG.dk), Copenhagen, Denmark.

P Ingeholm (P)

Department of Pathology, Herlev and Gentofte Hospital, Copenhagen, Denmark.

V E P P Lemmens (VEPP)

Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands; Department of Public Health, Erasmus MC, Rotterdam, the Netherlands.

G J Liefers (GJ)

Department of Surgical Oncology, Leiden University Medical Center, the Netherlands.

F A Holman (FA)

Department of Surgical Oncology, Leiden University Medical Center, the Netherlands.

J W T Dekker (JWT)

Department of Surgery, Reinier de Graaf Hospital, Delft, the Netherlands.

J E A Portielje (JEA)

Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.

H J Rutten (HJ)

Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands; GROW: School of Oncology and Developmental Biology, University of Maastricht, Maastricht, the Netherlands.

C J H van de Velde (CJH)

Department of Surgical Oncology, Leiden University Medical Center, the Netherlands. Electronic address: C.J.H.van_de_Velde@lumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH